Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon Therapeutics, a leading ophthalmic gene therapy company
LONDON: Syncona Ltd has signed an agreement for the sale of its portfolio company Clade Therapeutics to Century Therapeutics for $45 million. Century is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies. Syncona committed $30 million to…
LONDON, UK: Syncona Ltd’s newly established portfolio company has entered into an agreement with Freeline Therapeutics Holdings plc to acquire all of the shares of Freeline that Syncona does not currently own in an all-cash transaction. Syncona currently owns 49.7%…
LONDON, UK: Syncona Ltd announced that Martin Murphy is stepping down as Chair of Syncona Investment Management Limited (SIML) with Chris Hollowood taking on the role of Interim Chair and Chief Executive Officer (CEO) of SIML. Martin will continue to…
LONDON: Syncona Ltd, a leading healthcare company, announces the appointment of Dr Kemal Malik as a Non-Executive Director with immediate effect. Kemal has 30 years of experience in global pharmaceutical research and development and has been responsible for bringing many…